COPENHAGEN, October 31, 2025 – Danish biotech Bavarian Nordic (BAVA.CO) signed a new European Union framework contract for up to eight million smallpox and mpox vaccine doses, replacing a 2022 agreement.
The deal strengthens Europe’s pandemic preparedness capabilities and provides Bavarian Nordic with a significant revenue pipeline through 2026 and beyond.
Key Takeaways
- New EU framework contract covers up to 8 million doses
- 1.1 million doses already committed, 750,000 deliveries scheduled 2026
- Agreement replaces previous 2022 European Commission deal
Market reaction & context
The new procurement framework contract was awarded by the European Commission to enhance preparedness against smallpox and mpox outbreaks 1. Under the agreement, 1.1 million doses have already been committed, with 750,000 scheduled for delivery in 2026 2.
Bavarian Nordic remains the sole Western supplier of mpox vaccines, giving it a competitive advantage in the growing biosecurity market. The company’s Jynneos vaccine is approved in both the United States and European Union for smallpox and mpox prevention.
Production capacity and timing
The Danish company has significantly scaled its manufacturing capabilities over the past year. CEO Paul Chaplin previously indicated the company could produce two million doses in 2024, expanding to eight million doses in 2025 3.
This production ramp-up comes as global health authorities maintain heightened vigilance following recent mpox outbreaks. The World Health Organization declared mpox a public health emergency in 2024, driving increased government procurement of vaccines.
Recent humanitarian efforts
Beyond commercial contracts, Bavarian Nordic announced a donation of mpox vaccines to Africa CDC just three days ago to support outbreak response efforts on the continent 4. The company has also secured multiple contracts with undisclosed European countries, including a recent 440,000-dose order 5.
These humanitarian and commercial initiatives position Bavarian Nordic as a key partner for global health security efforts. The company’s vaccine stockpiling agreements provide steady revenue streams while supporting pandemic preparedness goals.
Financial implications
The framework contract structure allows for flexible ordering based on evolving public health needs. While specific financial terms were not disclosed, the up-to-eight-million-dose capacity represents substantial potential revenue for the biotech company.
Bavarian Nordic’s vaccine business has become increasingly important to its overall financial performance as governments prioritize biosecurity investments. The company’s specialized manufacturing capabilities and regulatory approvals create significant barriers to entry for potential competitors.
Not investment advice. For informational purposes only.
References
1“Bavarian Nordic Awarded New Procurement Framework Contract by the European Commission to Strengthen Preparedness Against Smallpox and Mpox”. Yahoo Finance. Retrieved October 31, 2025.
2“Bavarian Nordic signs EU smallpox and mpox vaccine contract for up to 8 million doses”. Reuters. Retrieved October 31, 2025.
3“Poxvirus vaccine maker could boost doses by 8 million next year”. STAT News. Retrieved October 31, 2025.
4Bavarian Nordic News. Bavarian Nordic. Retrieved October 31, 2025.
5Bavarian Nordic Search – Jynneos. Bavarian Nordic. Retrieved October 31, 2025.